The Synergism Or Long Duration (SOLD) Study
The purpose of the study is to compare disease-free survival (DFS) of women treated with concomitant trastuzumab plus docetaxel followed by FEC to that of the women treated with the same regimen followed by single-agent trastuzumab to complete one year of trastuzumab administration as adjuvant treatments of early HER2-positive breast cancer.
Breast Neoplasms
DRUG: trastuzumab (9 weeks) + docetaxel|DRUG: trastuzumab (9 weeks) + docetaxel + CEF + trastuzumab (up to 51 weeks)
Disease-free survival (DFS), 3-10years
Overall survival, distant disease-free survival, cardiac event-free disease-free survival, left ventricle ejection fractions, adverse events, quality of life, 3-10years
The purpose of the study is to compare disease-free survival (DFS) of women treated with concomitant trastuzumab plus docetaxel followed by FEC to that of the women treated with the same regimen followed by single-agent trastuzumab to complete one year of trastuzumab administration as adjuvant treatments of early HER2-positive breast cancer.